Renibus Therapeutics
PrivateLast Round
Series B
Sep 12, 2023
Total Funding Raised
$187M
Company Overview
Renibus Therapeutics operates in Healthcare & Life Sciences and is based in Southlake, Texas. Its latest recorded funding round was a Series B round in September 2023.
Renibus Therapeutics is a clinical-stage biopharmaceutical company that develops products to prevent disease progression, improve outcomes, and protect against organ damage associated with cardio, renal, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Renibus Therapeutics Comparables
Compare Renibus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AM-Pharma | 84% | |
| Arch Biopartners Inc. | 79% | |
| Revelation Biosciences Inc. | 79% |
For institutional investors. Book with your work email.
Renibus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 12, 2023 | ||||
| Series B | Jul 17, 2023 | ||||
| Debt | Aug 1, 2022 | ||||
| SAFE | Aug 1, 2022 | ||||
| Series A | Feb 15, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Renibus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oxford Finance | Debt |
| Bios Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors grew 98% MoM, reaching 3.7K.
- Mar 26, 2026
Attending the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 24, 2026
In Texas on Sep 24th '26, Renibus Therapeutics, Inc.'s lead program, veverimer, is in Phase 3 development to treat metabolic acidosis in adults with chronic kidney disease.
For institutional investors. Book with your work email.
Renibus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Renibus Therapeutics's valuation, stock price, and market status.
Is Renibus Therapeutics a public or private company?
Renibus Therapeutics is a private company.
What is the current stock price of Renibus Therapeutics?
Renibus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Renibus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Renibus Therapeutics worth (valuation)?
Valuation information for Renibus Therapeutics is not publicly available.
Can I buy Renibus Therapeutics stock?
Renibus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Renibus Therapeutics's last funding round?
Renibus Therapeutics's most recent funding round was Series B on September 12, 2023.
Who are the main investors in Renibus Therapeutics?
Key investors in Renibus Therapeutics include Oxford Finance, Bios Partners.
Will Renibus Therapeutics IPO soon?
No public IPO plans have been announced for Renibus Therapeutics.
How can I track Renibus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Renibus Therapeutics's shares on secondary markets.